Introduction {#ss1}
============

The prevalence of type 2 diabetes is increasing dramatically throughout the world; early detection of developing glucose intolerance is important to delay and prevent the disease. The American Diabetes Association (ADA) has lowered the cut‐off value of impaired fasting glucose (IFG) from 110 to 100 mg/dL in 2003. Subjects with fasting plasma glucose (FPG) from 100 to 109 mg/dL together with normal postchallenge glucose levels have been classified as normal glucose tolerance (NGT) by the criteria of the World Health Organization (WHO) and the Japanese Diabetes Society (JDS), but are classified as IFG by the 2003 ADA criteria[^1--3^](#b1 b2 b3){ref-type="ref"}. Insulin secretory capacity and insulin sensitivity are regulated differently with regard to fasting and postchallenge plasma glucose[^4,5^](#b4 b5){ref-type="ref"}, and therefore require separate evaluation. In addition, there are ethnic differences in the pathology of developing glucose intolerance. In our previous studies, impaired insulin secretion is shown to play an especially important role in both diabetic and pre‐diabetic Japanese subjects[^4,5^](#b4 b5){ref-type="ref"}, in contrast to the increasing insulin resistance that is the more important factor in Caucasian, Mexican American and Pima Indian populations[^6,7^](#b6 b7){ref-type="ref"}. In the present cross‐sectional study, we analyzed 1383 Japanese patients with fasting plasma glucose between 100 and 109 mg/dL (IFG~100--109~) to characterize and compare insulin secretory capacity, and insulin sensitivity of Japanese patients with IFG~100--109~ in the development of glucose intolerance.

Methods {#ss2}
=======

Subjects {#ss3}
--------

A total of 1835 Japanese patients undergoing 75‐g oral glucose tolerance test (OGTT) as a result of positive urine glucose test, ≥5.5% glycated hemoglobin (HbA~1c~) level, ≥100 mg/dL fasting plasma glucose (FPG) level, and family history of diabetes at initial examination for medical check‐up at Kyoto University Hospital, Ikeda Hospital, Kansai Electric Power Hospital, Kansai Health Management Center, Center for Preventive Medicine of St. Luke's International Hospital and Kyoto Preventive Medical Center from 1993 to 2009 were examined. Originally, 358 patients who had hypertension, hepatic or renal dysfunction, endocrine or malignant disease, or history of heavy exercise, gastrectomy, or medication known to affect glucose metabolism were excluded from 2193 patients. Among the 1835 patients, 470 patients were excluded because of fasting glucose levels ≥ 126 mg/dL and postchallenge glucose levels ≥ 140 mg/dL with FPG ≥ 110 mg/dL and FPG \< 100 for the present study, and 1383 patients were included. The study was designed in compliance with the ethics regulations of the Helsinki Declaration, and the study protocol was approved by the ethics committee of St. Luke's International Hospital.

Standard OGTT with 75‐g glucose was given according to the National Diabetes Data Group recommendations[^8^](#b8){ref-type="ref"}, which require patients to fast overnight for 10--16 h. Fasting, 0.5, 1, and 2‐h blood samples were obtained for measurement of plasma glucose and serum insulin after oral administration of 75‐g glucose. Blood samples for measurement of HbA~1c~, total cholesterol, high‐density lipoprotein cholesterol (HDL‐C) and triglyceride levels were collected after overnight fast.

The subjects that underwent 75‐g OGTT were divided into two groups: one having normal postchallenge glucose (2‐hPG \< 140 mg/dL) and another having IFG~100--109~ (100 ≤ FPG \< 110 mg/dL). The subjects of each group also were divided into three groups as shown in [Figure 1](#f1){ref-type="fig"}.

![ Subgroups of impaired fasting glucose. DM, diabetes mellitus; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; NGT, normal glucose tolerance.](jdi-3-377-g1){#f1}

Group one had normal postchallenge glucose: NGT (*n* = 594); normal fasting glucose according to ADA (FPG \< 100 mg/dL) with normal postchallenge glucose, IFG~100--109~/NGT (*n* = 369); IFG~100--109~ (100 ≤ FPG \< 110 mg/dL) with normal postchallenge glucose, IFG~110--125~/NGT (*n* = 160); and IFG (110 ≤ FPG \< 126 mg/dL) with normal postchallenge glucose. Group two had IFG~100--109~: IFG~100--109~/NGT (*n* = 369); IFG~100--109~ with normal postchallenge glucose, IFG~100--109~/IGT (*n* = 225); IFG~100--109~ with impaired glucose tolerance (IGT; 140 ≤ 2‐hPG \< 200 mg/dL), and IFG~100--109~/diabetes mellitus (DM; *n* = 35); IFG~100--109~ with postchallenge hyperglycemia (200 mg/dL ≤ 2‐hPG; [Figure 1](#f1){ref-type="fig"}).

Measurements {#ss4}
------------

Plasma glucose level was measured by the glucose oxidase method using a Hitachi Automatic Clinical Analyzer 7170 (Hitachi, Tokyo, Japan). Serum insulin was measured by two‐site radioimmunoassay (Insulin Riabead II; Dainabot, Tokyo, Japan), as reported previously[^9^](#b9){ref-type="ref"}. HbA~1c~ was measured by HLC‐723G7 (Tosoh, Tokyo, Japan). Coefficients of variation (CVs) were 0.56% for plasma glucose, \<7% for insulin and \<2% for HbA~1c~. Serum total cholesterol and triglycerides levels were measured as reported previously[^10^](#b10){ref-type="ref"}.

Blood samples were collected at 0, 30, 60 and 120 min after OGTT, and plasma glucose and serum insulin levels were measured for all subjects. Blood samples for measurements of HbA~1c~, total cholesterol, HDL‐C and triglycerides were drawn after an overnight fast. The HbA~1c~ value was estimated as a National Glycohemoglobin Standardization Program (NGSP) equivalent value calculated by the formula: HbA~1c~ (NGSP) = HbA~1c~ (JDS) + 0.4%, considering the relational expression of HbA~1c~ (JDS) measured by the previous Japanese standard substance and measurement methods and HbA~1c~ (NGSP)[^2^](#b2){ref-type="ref"}.

Early‐phase insulin secretion and systemic insulin sensitivity during OGTT were evaluated by insulinogenic index[^11--13^](#b11 b12 b13){ref-type="ref"}, and Insulin sensitivity was determined by an OGTT based on the formula for the composite of insulin sensitivity index (ISI composite)[^14^](#b14){ref-type="ref"}. Insulinogenic index \< 0.4 is considered in Japanese to be decreased early‐phase insulin secretion according to the 'Report of The Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus' by the Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus[^2^](#b2){ref-type="ref"}. The calculations were as follows:

We compared these two indices between IFG subgroups and NGT as shown in [Figure 1](#f1){ref-type="fig"} in this cross‐sectional study.

Statistical Analysis {#ss5}
--------------------

All of the statistical analyses were carried out using SPSS version 19.0 (SPSS Japan, Tokyo, Japan). Clinical characteristics of the study subjects are described using mean ± standard deviation, and general analysis of variance (ANOVA) was carried out for between‐group comparisons. The differences were established by *post‐hoc* Bonferroni test for multiple comparisons. *P*‐values \<0.05 were considered statistically significant. Multiple stepwise regression analysis was done using AUC‐G and 2‐h PG as the dependent variables, and age, body mass index (BMI), ISI composite and insulinogenic index as the independent variables among the IFG~100--109~ subgroups. In addition, simple regression analysis was applied between insulinogenic index and area under the curve of glucose (AUC‐G), and also between insulinogenic index and 2‐hPG, as the insulinogenic index showed the strongest relationship with these two factors.

Results {#ss6}
=======

Comparison of NGT, IFG~100--109~/NGT and IFG~110--125~/NGT {#ss7}
----------------------------------------------------------

### Clinical Characteristics {#ss8}

[Table 1](#t1){ref-type="table-wrap"} shows the clinical and metabolic characteristics of the 1123 Japanese patients classified with NGT, IFG~100--109~/NGT and IFG~110--125~/NGT. The age and BMI (mean ± standard error) of the total of the three groups were 51.3 ± 0.4 years and 22.9 ± 0.2, respectively. The mean age of the NGT group was significantly lower than that of the other two groups (*P* \< 0.05). The differences in BMI were significant among the three groups (*P* \< 0.05, respectively). There was no significant difference in triglycerides, total cholesterol or HDL‐C, although HbA~1c~ showed significant differences among the three groups (*P* \< 0.001, respectively).

######  Clinical and metabolic characteristics of NGT, IFG~100--109~/NGT and IFG~110--125~/NGT

                               NGT           IFG~100--109~/NGT   IFG~110--125~/NGT
  ---------------------------- ------------- ------------------- ------------------------
  *n*                          594           369                 160
  Age (years)                  48.6 ± 0.6    54.2 ± 0.6\*        54.7 ± 0.7\*
  BMI (kg/m^2^)                22.2 ± 0.1    23.1 ± 0.2          24.9 ± 1.2\*^,^\*\*
  FPG (mg/dL)                  90.3 ± 0.3    104.1 ± 0.2\*       114.8 ± 0.3\*^,^\*\*\*
  2‐h PG (mg/dL)               104.5 ± 0.8   112.8 ± 0.9\*       112.5 ± 1.5\*
  Fasting insulin (pmol/L)     33.3 ± 0.7    37.5 ± 1.0\*        40.2 ± 1.6\*
  HbA~1c~ (%)                  5.3 ± 0.0     5.7 ± 0.0\*         5.9 ± 0.0\*^,^\*\*\*
  Triglycerides (mmol/L)       1.26 ± 0.06   1.23 ± 0.05         1.28 ± 0.10
  Total cholesterol (mmol/L)   5.28 ± 0.06   5.34 ± 0.05         5.38 ± 0.09
  HDL cholesterol (mmol/L)     1.61 ± 0.03   1.63 ± 0.03         1.62 ± 0.05

Data are mean ± standard error. BMI, body mass index; FPG, fasting plasma glucose; HbA~1c~, glycated hemoglobin; HDL, high‐density lipoprotein; PG, plasma glucose. \**P *\< 0.05 (vs normal glucose tolerance \[NGT\]); \*\**P* \< 0.05 (vs impaired fasting glucose \[IFG\]~100--109~/NGT); \*\*\**P* \< 0.001 (vs IFG~100--109~/NGT).

### Insulin Secretion {#ss9}

The insulinogenic indices of the three groups are shown in [Figure 2a](#f2){ref-type="fig"}; NGT 0.48, IFG~100--109~/NGT 0.39, IFG~110--125~/NGT 0.27. The insulinogenic index in the NGT group was significantly higher than that in the other groups (*P* \< 0.05). The insulinogenic index in the IFG~100--109~/NGT group was \<0.4.

![ Indices of insulin secretion and sensitivity. (a) Early‐phase insulin secretion. Insulinogenic index in normal glucose tolerance (NGT) is highest and shows significant differences compared with the other two groups (NGT and impaired fasting glucose (IFG)~100--109~/NGT: *P *= 0.026, NGT and IFG~110--125~/NGT: *P *≤ 0.001). (b) Insulin sensitivity. Insulin sensitivity index (ISI) composite in NGT is significantly higher than the other groups. (NGT and IFG~100--109~/NGT: *P *≤ 0.001, NGT and IFG~110--125~/NGT: *P *≤ 0.001). (c) Early‐phase insulin secretion. The difference of insulinogenic index is significant except between IFG~100--109~/impaired glucose tolerance (IGT) and IFG~100--109~/diabetes mellitus (DM; IFG~100--109~/NGT and IFG~100--109~/IGT: *P *= 0.023, IFG~100--109~/NGT and IFG~100--109~/DM: *P *= 0.013). (d) Insulin sensitivity. The difference of ISI composite is significant only between IFG~100--109~/NGT and IFG~100--109~/IGT (IFG~100--109~/NGT and IFG~100--109~/IGT: *P *≤ 0.001). \**P* \< 0.05; \*\**P* \< 0.001. NS, not significant.](jdi-3-377-g2){#f2}

Insulin Sensitivity {#ss10}
-------------------

[Figure 2b](#f2){ref-type="fig"} shows the ISI composites: NGT 10.3, IFG~100--109~/NGT 7.9, IFG~110--125~/NGT 7.2. ISI composite in the NGT was significantly higher than in the other groups (*P* \< 0.001).

Comparison of IFG~100--109~/NGT, IFG~100--109~/IGT and IFG~100--109~/DM {#ss11}
-----------------------------------------------------------------------

### Clinical Characteristics {#ss12}

[Table 2](#t2){ref-type="table-wrap"} shows the clinical and metabolic characteristics of the 629 Japanese patients classified with IFG~100--109~/NGT, IFG~100--109~/IGT and IFG~100--109~/DM. The age and BMI (mean ± standard error) of all of the patients were 55.2 ± 0.4 years and 23.5 ± 0.1, respectively. However, the BMI of IFG~100--109~/NGT subjects were significantly lower (*P* \< 0.05). There was a significant difference in age only between IFG~100--109~/NGT and IFG~100--109~/DM. The differences in triglycerides and total cholesterol were significant only between IFG~100--109~/NGT and IFG~100--109~/IGT (*P* \< 0.05). There was no significant difference in HDL‐C, except for HbA~1c~, which showed significant differences among the three groups (*P* \< 0.001, respectively).

######  Clinical and metabolic characteristics of IFG~100--109~/NGT, IFG~100--109~/IGT and IFG~100--109~/DM

                               IFG~100--109~/NGT   IFG~100--109~/IGT   IFG~100--109~/DM
  ---------------------------- ------------------- ------------------- --------------------------
  *n*                          369                 225                 35
  Age (years)                  54.2 ± 0.6          56.3 ± 0.7          58.9 ± 1.9\*
  BMI (kg/m^2^)                23.1 ± 0.2          24.0 ± 0.2          24.6 ± 0.8\*
  FPG (mg/dL)                  104.1 ± 0.2         104.7 ± 0.3\*       105.1 ± 0.5
  2‐h PG (mg/dL)               112.8 ± 0.9         161.8 ± 1.1\*\*     223.8 ± 3.7\*\*^,^\*\*\*
  Fasting insulin (pmol/L)     37.5 ± 1.0          44.6 ± 1.9\*\*      41.2 ± 3.9
  HbA~1c~ (%)                  5.7 ± 0.0           5.8 ± 0.0\*\*       6.2 ± 0.1\*\*^,^\*\*\*
  Triglycerides (mmol/L)       1.23 ± 0.05         1.64 ± 0.11\*\*     1.35 ± 0.13
  Total cholesterol (mmol/L)   5.34 ± 0.05         5.54 ± 0.07\*       5.54 ± 0.17
  HDL cholesterol (mmol/L)     1.63 ± 0.03         1.53 ± 0.04         1.59 ± 0.12

Data are mean ± standard error. BMI, body mass index; FPG, fasting plasma glucose; HbA~1c~, glycated hemoglobin; HDL, high‐density lipoprotein; PG, plasma glucose. \**P *\< 0.05 (vs impaired fasting glucose \[IFG\]~100--109~/normal glucose tolerance \[NGT\]); \*\**P* \< 0.001 (vs IFG~100--109~/NGT); \*\*\**P* \< 0.001 (vs IFG~100--109~/impaired glucose tolerance \[IGT\]).

### Insulin Secretion {#ss13}

The insulinogenic indices of the three groups are shown in [Figure 2c](#f2){ref-type="fig"}. The insulinogenic index showed a significant difference between IFG~100--109~/NGT and the others (*P* \< 0.05), and the insulinogenic index of IFG~100--109~/DM (0.19) was nearly 50% compared with IFG~100--109~/NGT (0.39). The insulinogenic index (II) in the IFG~100--109~/NGT (0.39) group was \<0.4.

### Insulin Sensitivity {#ss14}

[Figure 2d](#f2){ref-type="fig"} shows the ISI composite of the three groups. There was a significant difference only between IFG~100--109~/NGT and IFG~100--109~/IGT (*P* \< 0.001), which showed a 9% decline from IFG~100--109~/NGT (7.9) to IFG~100--109~/DM (7.2).

### Simple and Multiple Regression Analysis {#ss15}

We examined the relationship between the dependent variables AUC‐G and 2‐hPG, and the independent variables of age, BMI, ISI composite and insulinogenic index by multiple regression analysis. Insulinogenic index showed the strongest relationship with AUC‐G and 2‐hPG (β of 2 h‐PG: age 0.11, BMI 0.10, II −0.215, ISI composite −0.164; and β of AUC‐G: age 0.082, BMI 0.048, II −0.545, ISI composite −0.350). [Figure 3a](#f3){ref-type="fig"} shows scattered plots of simple regression analysis of AUC‐G with insulinogenic index and ISI composite. Insulinogenic index (*r* = 0.454, *P* \< 0.001, *F*‐value 16.3) had a stronger relationship with AUC‐G than with ISI composite (*r* = 0.232, *P* \< 0.001, *F*‐value 35.7). [Figure 3b](#f3){ref-type="fig"} shows scattered plots of simple regression analysis of 2‐hPG with insulinogenic index and ISI composite. Insulinogenic index (*r* = 0.165, *P* \< 0.001, *F*‐value 17.5) was more related to 2‐hPG than to ISI composite (*r* = 0.150, *P* \< 0.001, *F*‐value 14.5).

![(a) The relationship between area under the curve of glucose (AUC‐G), and insulinogenic index and insulin sensitivity index (ISI) composite among the impaired fasting glucose (IFG)~100--109~ groups. Insulinogenic index (*r* = 0.454, *P* \< 0.001, *F*‐value 16.3) was more related to AUC‐G than ISI composite (*r* = 0.232, *P* \< 0.001, *F*‐value 35.7). (b) The relationship between 2‐h postchallenge glucose level (PG‐120), and insulinogenic index and ISI composite. Insulinogenic index (*r* = 0.165, *P* \< 0.001, *F*‐value 17.5) was more related to PG‐120 than ISI composite (*r* = 0.150, *P* \< 0.001, *F*‐value 14.5).](jdi-3-377-g3){#f3}

Discussion {#ss16}
==========

In the present study, we analyzed insulin secretory capacity and insulin sensitivity in a cross‐sectional study in Japanese subjects who had IFG~100--109~ (IFG~100--109~; 100 ≤ FPG \< 110 mg/dL). A reduction in the insulinogenic index, a measure of early‐phase insulin secretion, has already begun in IFG~100--109~/NGT subjects, for which the insulinogenic index was 0.39 ([Figure 2a](#f2){ref-type="fig"}). The ISI composite, an index of systemic insulin sensitivity, is also decreased in the deterioration of FPG from NGT through IFG~100--109~/NGT to IFG~110--125~/NGT ([Figure 2b](#f2){ref-type="fig"}). IFG~100--109~/NGT subjects are classified into normal fasting glucose tolerance according to the 1998 WHO criteria and the criteria of the JDS, although they are classified into IFG based on the 2003 ADA criteria. There are numerous studies of impaired fasting glucose that justify the new ADA criteria, but few studies focus on the borderline IFG~100--109~ group regarding the relevance of insulin secretory capacity and insulin sensitivity in the development of disease. The present study showed deterioration of both early‐phase insulin secretion and insulin sensitivity in IFG~100--109~/NGT. To clarify the pathology, we evaluated IFG~100--109~ subjects in three subgroups: IFG~100--109~/NGT, IFG~100--109~/IGT and IFG~100--109~/DM. The mean insulinogenic indices were found to decrease from IFG~100--109~/NGT through IFG~100--109~/IGT to IFG~100--109~/DM (0.39 \[\<0.40\], 0.30 and 0.19, respectively), and those of IFG~100--109~/IGT and IFG~100--109~/DM were significantly lower than that of IFG~100--109~/NGT. In contrast, the differences among ISI composites in IFG~100--109~/NGT, IFG~100--109~/IGT and IFG~100--109~/DM were small. In addition, IFG~100--109~/DM showed a stronger deterioration in insulin secretory capacity and insulin sensitivity than in IFG~110--125~/NGT (*P *\< 0.05). These results agree with those of our previous studies in Japanese subjects that show that impairment of early‐phase insulin secretion plays the more important role in the deterioration of postchallenge glucose tolerance, whereas insulin resistance plays a lesser role[^15^](#b15){ref-type="ref"}.

It is notable that IFG~100--109~/IGT and IFG~100--109~/DM are included into IFG~100--109~ if judged only by FPG. Although this study is not a population‐based study, over 40% of the subjects with IFG~100--109~ also were classified as IGT or DM. This suggests that DM, as well as IGT, might be overlooked when screening by FPG among subjects with IFG~100--109~. IFG has been reported as high risk for developing type 2 diabetes. In a study of Japanese subjects, those with IFG~100--109~ developed type 2 diabetes at twice the rate as NGT during 4 years[^16^](#b16){ref-type="ref"}. Bonora *et al.*[^17^](#b17){ref-type="ref"} found that diabetic incidence rates for 10 years of IGT, IFG and IFG/IGT were 3.9, 11 and 20.5 compared with that of NGT, respectively. Meigs *et al.*[^18^](#b18){ref-type="ref"} found that 40% of isolated IFG progressed to diabetes. According to the Funagata study, the risk for type 2 diabetes in Japanese with isolated IFG is 20.5 compared with that in NGT[^19^](#b19){ref-type="ref"}. IFG subjects, therefore, require checking of postchallenge plasma glucose levels by OGTT to prevent or delay diabetes.

Regarding insulin secretory capacity and insulin sensitivity, fasting and postchallenge plasma glucose levels are regulated differently[^20^](#b20){ref-type="ref"}. Hyperglycemia in Japanese patients is typically as a result of factors that differ from those in other ethnic groups, impaired insulin secretion and sensitivity being most notable. We have previously reported that although impaired early‐phase insulin secretion plays the more important role in deterioration from NGT through IGT to isolated postchallenge hyperglycemia in Japanese subjects[^9^](#b9){ref-type="ref"}, progression from NGT through IFG to isolated fasting hyperglycemia is associated with both impaired insulin secretion and decreased insulin sensitivity[^21^](#b21){ref-type="ref"}. However, impaired insulin secretion is the more important factor in Japanese subjects, whereas increasing insulin resistance is the more important factor in Caucasians, Mexican Americans and Pima Indians[^7,22^](#b7 b22){ref-type="ref"}. The mean BMI of Japanese diabetics is 23--25 according to various epidemiological studies, which is lower than that in other ethnic groups[^4,23^](#b4 b23){ref-type="ref"}. It has also been reported that the insulinogenic index in IGT is greater than that in NGT in Caucasians, in whom insulin secretion peaks at 121 mg/dL of plasma glucose[^24^](#b24){ref-type="ref"} compared with 100 mg/dL in Japanese[^25^](#b25){ref-type="ref"}. The diversities in these groups suggest the importance of characterizing both insulin secretion and sensitivity in the different stages of glucose intolerance. In the present study, for the prevention of type 2 diabetes and the selection of suitable treatments, we analyzed IFG~100--109~, which has not been addressed with regard to insulin secretory capacity and insulin sensitivity. The present results in Japanese subjects with IFG~100--109~ show that lesser reserve capacity of insulin secretion rather than greater insulin resistance is involved in deteriorating 2‐hPG and AUC‐G.

We have found that deterioration of both insulin secretory capacity and insulin sensitivity has already begun in IFG~100--109~/NGT. In addition, early‐phase insulin secretion plays an important role in the deterioration of postchallenge glucose levels among Japanese subjects with slightly impaired fasting glucose of IFG~100--109~, whereas insulin sensitivity plays a more limited role. Over 40% of IFG~100--109~ subjects were classified into IGT or diabetes according to 2‐hPG during OGTT. Therefore, Japanese IFG~100--109~ subjects classified into normal glucose tolerance according to the WHO criteria and the JDS criteria are recommended to be screened by OGTT to identify whether they are NGT, IGT or diabetes.
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